MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
LAA Closure With the Watchman Device
A review of techniques and clinical studies.
By Arun Kanmanthareddy, MD; Yeruva Madhu Reddy, MD; Jayasree Pillarisetti, MD; Vijay Swarup, MD; and Dhanunjaya Lakkireddy, MD
Ask the Experts: What is the impact of the Watchman approval on structural practice? What are the roles of the electrophysiology and interventional cardiology physician?
By Dhanunjaya Lakkireddy, MD, FACC, FHRS, and Brian Whisenant, MD
Abbott’s Amplatzer Amulet LAA Occluder in AFib Evaluated at 5 Years in IDE Trial
November 22, 2024—Abbott recently announced late-breaking data for the company’s Amplatzer Amulet left atrial appendage (LAA) occluder to treat patients with atrial fibrillation (AFib) who are at an increased risk of stroke.
Abbott’s Amplatzer Amulet LAA Occluder Device Approved by FDA
August 16, 2021—Abbott announced FDA approval of the company’s Amplatzer Amulet left atrial appendage (LAA) occluder for the treatment of patients with atrial fibrillation who are at risk of ischemic stroke.
St. Jude Medical Launches MediGuide Technology
October 8, 2012—St.
AMAZE Will Study SentreHeart's Lariat for Ligation of the LAA as Adjunctive Treatment for AF
June 25, 2015—SentreHeart, Inc. announced that it has received approval for an investigational device exemption from the US Food and Drug Administration (FDA) to begin enrollment in the AMAZE clinical trial of the Lariat suture delivery device for the ligation of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AF).
Valvular Interventions
By Ted E. Feldman, MD, FESC, FACC, FSCAI
Global Amplatzer Amulet IDE Trial Evaluates St. Jude Medical's Next-Generation LAA Occluder
September 6, 2016—St.
Abbott’s Amplatzer Amulet LAA Occluder Late-Breaking Data Presented at ESC Congress
August 30, 2021—Abbott announced late-breaking data from the Amulet investigational device exemption (IDE) trial of the company’s Amplatzer Amulet left atrial appendage (LAA) occluder device for the treatment of patients with atrial fibrillation (AFib) at an increased risk of stroke.
Structural Disease Update
By Ted E. Feldman, MD, MSCAI, FACC, FESC
FDA Clears St. Jude's ViewFlex Xtra ICE Catheter
July 12, 2012—St.
